Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.
Cullgen_logo_FINAL_4-21-2020_transparent_PNG

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients

CG001419 is Cullgen’s first protein degrader to enter clinical development SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company...